Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir Regimens

NCT07631897 | Not Yet Recruiting Phase 4

• 1 other identifier: 2026-S031
• Study Type: interventional
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a prospective, multicenter, open-label, parallel-controlled study. The primary objective is to prospectively explore and compare the virological efficacy of Ainuovirine/Lamivudine/Tenofovir and Efavirenz/Lamivudine/Tenofovir regimens combined with rifampicin and isoniazid-based anti-tuberculosis therapy in HIV-infected patients with active tuberculosis. Participants are divided into two groups to compare the virological suppression rate and immunological efficacy between the two antiretroviral regimens. All subjects will receive continuous antiretroviral medication and anti-tuberculosis drugs under medical supervision throughout the study.

Conditions

Art Therapy; HIV; TB - Tuberculosis

Outcome Measures

Primary Outcomes (1)

• Viral suppression rates of two antiretroviral therapy(ART) regimens at week 48

  Percentage of HIV RNA virological suppression (HIV RNA viral load \<50 copies/mL) in two groups treated with Ainuovirine-based regimen or TLE regimen for 48 weeks

  at week 48

Secondary Outcomes (5)

• Immunological efficacy (CD4+ T cell count) of the two groups at week 48

  at week 48

• ART treatment failure rate of the two groups

  at week 48

• Evaluate the anti-tuberculosis treatment outcomes of two groups, with primary indicators of cure rate and treatment failure rate

  at week 48

• Incidence rates of all-grade adverse events and grade ≥3 adverse events in the two groups

  through study completion, about 48 weeks

• Types and constituent ratios of adverse events above grade 1 in the two groups

  through study completion, about 48 weeks

Study Arms (2)

TLE group

ACTIVE COMPARATOR

Antiretroviral therapy is initiated 14 days after participants receive anti-tuberculosis treatment consisting of rifampicin and isoniazid. The regimen is Efavirenz 400 mg, Lamivudine 300 mg and Tenofovir Disoproxil Fumarate 300 mg, one tablet of each taken once daily.

Drug: Tenofovir, Lamivudine and Efavirenz Disoproxil Fumarate Tablets

ALT group

EXPERIMENTAL

Antiretroviral therapy is initiated 14 days after participants receive anti-tuberculosis treatment with rifampicin and isoniazid. The regimen is Ainuovirine 150mg, Lamivudine 300mg and Tenofovir 300mg, one tablet each time, once daily.

Drug: Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets

Interventions

Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets DRUG

Antiretroviral therapy is initiated 14 days after participants receive anti-tuberculosis treatment with rifampicin and isoniazid. The regimen is Ainuovirine 150mg, Lamivudine 300mg and Tenofovir 300mg, one tablet each time, once daily.

ALT group

Tenofovir, Lamivudine and Efavirenz Disoproxil Fumarate Tablets DRUG

Antiretroviral therapy is initiated 14 days after participants receive anti-tuberculosis treatment consisting of rifampicin and isoniazid. The regimen is Efavirenz 400 mg, Lamivudine 300 mg and Tenofovir Disoproxil Fumarate 300 mg, one tablet of each taken once daily.

TLE group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged between 18 and 65 years;
• Body weight ≥ 40 kg with BMI ranging from 18.5 to 30 kg/m²;
• Treatment-naïve patients with HIV-1 infection who are planned to initiate antiretroviral therapy;
• Diagnosed with active Mycobacterium tuberculosis infection and receiving anti-tuberculosis regimen containing rifampicin and isoniazid;
• CD4⁺ T cell count ≥ 25 cells/μL;
• HIV RNA viral load \< 500,000 copies/mL;
• Subjects who can fully understand the nature, methods and potential adverse reactions of this trial, comply with the requirements stated in the informed consent form, and voluntarily sign the informed consent form.

You may not qualify if:

• Subjects with allergic constitution or a history of allergy to the study drugs and excipients;
• Those with a history of drug addiction, substance abuse, or chronic alcoholism;
• Pregnant or lactating women; women of childbearing potential who cannot adopt effective contraceptive measures (e.g., contraceptive diaphragm, condom, intrauterine device, partner vasectomy), or whose sexual partners fail to implement effective contraception;
• Subjects who have used drugs with moderate to high drug drug interaction potential with the study drugs (excluding anti tuberculosis drugs) within 2 weeks prior to formal enrollment and ART initiation (only applicable to the pre trial phase);
• Those who are unable to receive oral anti tuberculosis treatment during antiretroviral therapy;
• Subjects with baseline drug resistance test results showing resistance to NNRTIs, 3TC or TDF;
• Those with resistance to one or more anti tuberculosis drugs;
• Subjects diagnosed or tentatively diagnosed with tuberculous meningitis;
• Patients complicated with other severe opportunistic infections besides Mycobacterium tuberculosis infection;
• Abnormal liver function: alanine transaminase (ALT)/aspartate transaminase (AST) \> 3×ULN with clinical symptoms, or \> 5×ULN without symptoms; total bilirubin (TBil) \> 2×ULN;
• Impaired renal function: estimated glomerular filtration rate (eGFR) calculated by the CKD EPI formula \< 60 mL/min/1.73 m²;
• Subjects complicated with tumors, severe neurological or psychiatric diseases, metabolic disorders, gastrointestinal diseases or other comorbidities that, in the investigator's judgment, may affect their participation and completion of the study;
• Any other conditions deemed inappropriate for enrollment by the investigator.

Sponsors & Collaborators

• Shanghai Public Health Clinical Center: lead

MeSH Terms

Conditions

Latent Tuberculosis

Interventions

Lamivudine; Tenofovir

Condition Hierarchy (Ancestors)

Tuberculosis; Mycobacterium Infections; Actinomycetales Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Latent Infection

Intervention Hierarchy (Ancestors)

Zalcitabine; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Deoxyribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Dideoxynucleosides; Organophosphonates; Organophosphorus Compounds; Organic Chemicals; Adenine; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Central Study Contacts

Jun Chen

CONTACT

021-37990333; chenjun@shaphc.org

Ling Gu

CONTACT

021-37990333; guling@shaphc.org

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief Physician

Study Record Dates

• First Submitted: May 25, 2026
• First Posted: June 8, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): June 1, 2028
• Study Completion (Estimated): December 1, 2028
• Last Updated: June 8, 2026

Record last verified: 2026-06